Janus Henderson Group PLC Buys 8,100 Shares of Dianthus Therapeutics, Inc. $DNTH

Janus Henderson Group PLC grew its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 96.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 16,500 shares of the company’s stock after buying an additional 8,100 shares during the period. Janus Henderson Group PLC’s holdings in Dianthus Therapeutics were worth $1,384,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after buying an additional 618 shares during the last quarter. American Century Companies Inc. lifted its position in Dianthus Therapeutics by 13.2% during the second quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock valued at $1,009,000 after purchasing an additional 6,323 shares during the period. Invesco Ltd. lifted its position in Dianthus Therapeutics by 31.1% during the second quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock valued at $390,000 after purchasing an additional 4,962 shares during the period. Alliancebernstein L.P. boosted its holdings in Dianthus Therapeutics by 14.5% in the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock worth $21,887,000 after purchasing an additional 149,200 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Dianthus Therapeutics in the second quarter worth approximately $27,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

DNTH opened at $108.92 on Monday. The stock has a market cap of $5.95 billion, a price-to-earnings ratio of -26.25 and a beta of 1.22. The firm’s fifty day moving average is $94.72 and its 200 day moving average is $80.90. Dianthus Therapeutics, Inc. has a fifty-two week low of $18.08 and a fifty-two week high of $114.55.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. On average, equities research analysts predict that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Insider Transactions at Dianthus Therapeutics

In other news, SVP Adam M. Veness sold 30,000 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the sale, the senior vice president directly owned 30,000 shares in the company, valued at $2,424,000. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Simrat Randhawa sold 26,530 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $362,480. This trade represents a 86.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 253,779 shares of company stock worth $25,931,495. 3.02% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on DNTH shares. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Truist Financial upped their price objective on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research report on Thursday. Finally, HC Wainwright increased their target price on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $124.27.

Dianthus Therapeutics News Roundup

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target for Dianthus Therapeutics to $158 from $130 and maintained a “Buy” rating. The target implies additional upside and reflects the firm’s long-term expectations for the company’s complement-therapy pipeline. Dianthus Therapeutics Price Target Raised to $158
• Positive Sentiment: HC Wainwright improved several near- and long-term earnings forecasts, including narrowing its estimated 2026 loss to $3.87 per share from $4.81 and projecting a return to profitability by 2030 at $10.75 per share. The firm continues to rate DNTH “Buy” with a $158 target. HC Wainwright Dianthus Therapeutics estimates
• Positive Sentiment: Institutional interest has expanded, led by BlackRock’s approximately $402 million new position. Institutional investors now own about 47.5% of the stock, which may reinforce investor confidence and liquidity. Dianthus Therapeutics institutional ownership and insider trading
• Neutral Sentiment: Analyst views are generally favorable but not unanimous. DNTH has a “Moderate Buy” consensus, with 12 Buy ratings and one Sell rating; the average price target is $124.27, below HC Wainwright’s $158 objective. Analysts conflicted on Dianthus Therapeutics
• Negative Sentiment: CEO Marino Garcia sold 166,000 shares for approximately $17.9 million, reducing his direct holdings by 71.8%. Although the sale may be part of personal financial planning, its size can weigh on sentiment, particularly after the stock’s strong advance. Dianthus Therapeutics CEO stock sale
• Negative Sentiment: The company remains loss-making and recently missed quarterly EPS expectations, reporting a $0.90 loss per share versus an expected $0.85 loss. Revenue exceeded estimates, but the result highlights continued execution and funding risks for this clinical-stage biotech.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.